ONWARD Medical
Company · Eindhoven, Netherlands
Uses spinal cord stimulation to restore movement after spinal cord injury and pairs it with BCIs for thought-driven walking.
ONWARD’s external ARC-EX system received FDA De Novo authorization in December 2024 to improve hand strength after spinal cord injury. With Clinatec and EPFL it is developing ARC-BCI, a “digital bridge” that links brain signals to spinal stimulation.
In the news
NeuromodulationClinical trials
ONWARD Medical reports 31 participants enrolled in its pivotal spinal cord stimulation trial
The company's third-quarter update also reported €2.5 million in revenue, 88 ARC-EX systems sold or supplied, and first implants in two smaller ARC-IM feasibility studies.
FundingNeuromodulation
ONWARD Medical raises more than €50 million to advance spinal cord stimulation therapies
Prosthetics maker Ottobock anchored the private placement, which funds the implantable ARC-IM program and ARC-EX sales.